Meeting
2023 ASCO Annual Meeting
Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.
Authors
Andrew Trunk
Cleveland Clinic (Cleveland, OH), Cleveland, OH
Andrew Trunk , Margaret Kelsey Baron , Jarrod Smith , Lisa M. Pappas , Ben Haaland , Vaia Florou , Christopher Duane Nevala-Plagemann , Ignacio Garrido-Laguna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3591)
DOI
10.1200/JCO.2023.41.16_suppl.3591
Abstract #
3591
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.
First Author: Joleen M. Hubbard
Poster
2022 ASCO Gastrointestinal Cancers Symposium
WJOG13219G: Triplet versus doublet in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).
First Author: Keitaro Shimozaki
Poster
2019 Gastrointestinal Cancers Symposium
The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
First Author: Chihiro Kosugi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of low- versus high-dose continuous 5FU infusion in patients receiving triplet chemotherapy plus bevacizumab for newly diagnosed metastatic colorectal cancer (mCRC).
First Author: William Joseph Chapin